REMEGEN

9995
63.5004.80% ( -3.200 )
Delay Closed: Nov 16, 16:08:11

Overview

REMEGEN (9995)

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, an...

Open
64.500
High
64.750
Low
62.550
Prev. Close
66.700
Volume
3.24M
Turnover
205.21M
Avg Price
63.390
Bid/Ask Ratio
-75.00%
Amplitude
3.30%
52wk High
123.100
Volume Ratio
0.64
Turnover Ratio
1.55%
52wk Low
60.000
HK Mkt Cap
13.24B
Market CapHKD
35.84B
P/ETTM
4.71
P/EDynamic
4.38
P/EStatic
--
EPSTTM
13.48
EPSDynamic
14.51
EPSStatic
--
BVPS
18.35
P/B
3.46
HK Shares
208.58M
Dividend YieldTTM
--
DividendTTM
--
Shares
564.48M
Min lot size
500
Currency
HKD

REMEGEN Analyst Rating

View more

Forecast & Rating

Nov 4, 2026
Price forecast
HK$115.4881.86%
Forecast & RatingBuy
16analysts
  • Strong buy68.75%
  • Buy12.50%
  • Hold18.75%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 16

    RemeGen fell 4.80% to HK$63.50 from a previous close of HK$66.70, tracing a dip-then-recover shape: it printed HK$62.70 at 09:31 and rebounded to HK$64.40 by 13:21, yet the centre of gravity stayed lower, and local coverage flagged an intraday drop of as much as 6%, consistent with the absence of fresh catalysts after the amended Vor Bio licence agreement and the addition of autoimmune candidate RC298 to that partnership. The gap between reported fundamentals and the tape is wide: Q2 2026 revenue reached HK$6.00bn (+857.75% yoy) with net profit of HK$5.01bn (+2437.85%), while Q3 net profit of HK$715m still grew 746.63% yoy but the net margin narrowed from 83.40% to 67.10%. At HK$63.50 the shares sit below the MA20 of HK$66.46 and MA60 of HK$72.36, down 13.78% year-to-date, 48.42% below the 19 April 52-week high of HK$123.10 and only 5.83% above the 22 October low of HK$60.00. Still, an afternoon recovery of more than 1.7% off the low and a majority of brokers carrying buy ratings point to some support near the bottom of the range.

  2. Nov, 6

    RemeGen fell 1.5% to HK$70.20 from HK$71.30, tracing a spike-and-fade session with an intraday range of HK$67.55 to HK$72.15. The pullback followed a broad Hong Kong biopharma rally, a joint A/H share advance and a RMB30 million to RMB60 million A-share buyback plan that had lifted sentiment, with today's action reflecting profit-taking after the prior move. Fundamentals remain strong: Q3 revenue was HK$1.065 billion, up 56.7% yoy, net profit HK$714.8 million, up 746.6%, and net margin 67.1%, though both revenue and profit were well below Q2's HK$6.003 billion and HK$5.006 billion. At HK$70.20 the shares sit above the 20-day MA of HK$66.25 but below the 60-day MA of HK$73.53, down 4.7% YTD and about 43% below the 52-week high of HK$123.10. Still, sector volatility remains high, with the stock having fallen 6% in a single session a day earlier.

  3. Nov, 4

    RemeGen opened lower but rallied through the session, accelerating in the afternoon to an intraday HK$70.90 and closing at HK$70.25, up 12.3% from the previous close of HK$62.55 on HK$335.4 million turnover and a 2.38% turnover rate. The move combined a fresh buyback with a swing to profit: the company proposed an A-share repurchase of RMB 30-60 million at a cap of RMB 131 per share, while Q3 revenue reached HK$1.065 billion (+56.7% yoy), net profit HK$714.8 million (+746.6%), net margin 67.1% and R&D spending down 22% yoy. BOCOM International kept a Buy rating with an HK$128 target. The stock is back above its MA20 of HK$66.28 but still below the MA60 of HK$73.94, 42.9% under the 52-week high of HK$123.1 and down 4.6% year to date. However, the net margin eased from 83.4% in Q2 to 67.1% in Q3, so the durability of single-quarter profitability still needs confirmation from later filings.

  4. Nov, 3

    RemeGen closed down 5.08% at HK$62.55, fading from an intraday high of HK$66.30 to a low of HK$61.65 as innovative-drug concept stocks weakened broadly and reports of a roughly 6% single-day drop in the shares added pressure. The operating backdrop looked different: Q3 revenue reached HK$1.065 billion, up 56.71% year on year, while net profit was HK$714.8 million, up 746.63%, alongside a proposed A-share buyback of RMB30 million to RMB60 million and a licensing deal with AbbVie for RC148. The stock remains 49.19% below its 52-week high of HK$123.10 and just 4.25% above its 52-week low of HK$60, down 15.07% year to date and below both its MA20 of HK$66.485 and MA60 of HK$74.184. Still, turnover was only HK$156.1 million with a 1.18% turnover rate, so the extent of selling-pressure release under lighter volume remains to be seen.

  5. Oct, 22

    Hong Kong biopharma names pulled back and RemeGen gapped up then faded: it opened at HK$67.10, which was also the session high, slid to HK$62.20 by 13:32 BJ and closed at HK$62.90 on HK$147m turnover, with weakness in CRO peers such as GenScript Bio and Akeso the main drag. Q2 2026 revenue of HK$6.00bn and net profit of HK$5.01bn, up 857.75% and 2437.85% year on year, with an 83.4% net margin and a PE of 5.3, stand in contrast to the price action. At HK$62.90 the stock sits 48.9% below its April 52-week high of HK$123.10 and only 1.45% above its 21 October low of HK$62.00, down 14.6% YTD and beneath its MA20 of HK$70.51 and MA60 of HK$76.50. RemeGen had repurchased 60,000 shares by end-September, though continued outflows from the sector have capped rebounds.

News

Bullish vs. Bearish — Last 3 Months

7.0k followers · 0 opinions
▲Bullish50%
50%Bearish▼